Metolazone Tablets IP 5 Mg - ZONACOR 5 Tablets

LORINTA 90 Tablets
Ticagrelor 90 mg

LORINTA 90 Tablets  – Ticagrelor Tablets IP 90 Mg contains Ticagrelor 90 mg, a next-generation antiplatelet agent that selectively and reversibly inhibits the P2Y12 ADP receptor on platelets. This mechanism prevents platelet activation and aggregation, thereby reducing the risk of thrombus formation. Unlike irreversible inhibitors such as clopidogrel, Ticagrelor’s reversible binding ensures potent yet controllable platelet inhibition with quicker restoration of platelet function when needed. It offers enhanced efficacy and safety in patients with acute coronary syndromes (ACS), providing reliable protection against ischemic events.

Key Points of Metolazone Tablets IP 5 Mg – ZONACOR 5 Tablets
• Superior Platelet Inhibition: Delivers faster and more consistent platelet suppression than clopidogrel.
• Cardiovascular Event Reduction: Significantly decreases the risk of myocardial infarction, stroke, and stent thrombosis.
• Reversible & Safer Profile: Allows flexible management during bleeding or surgical procedures.

Can be Prescribed by:
• Cardiology
• Cardiothoracic Surgery
• Internal Medicine
• Critical Care Medicine
• Emergency Medicine
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.